Clinical Trials
Numerous clinical trials and observational studies evaluate ritonavir across Phase 1 to Phase 4, focusing predominantly on HIV infections, COVID-19, chronic hepatitis delta, and hepatitis C. Sponsored by pharmaceutical corporations, government entities, and academic institutions, these initiatives span planned, active, and completed recruitment stages. Ultimately, these studies evaluate ritonavir's pharmacokinetic boosting capabilities and therapeutic efficacy across varied indications.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06337032 | RECRUITING | HIV-1-infection |
Gilead Sciences |
2024-08-27 | PHASE4 |
| NCT07792096 | NOT_YET_RECRUITING | HIV Infection |
University College, London |
2026-11 | PHASE3 |
| NCT04381936 | RECRUITING | Pneumonia |
University of Oxford |
2020-03-19 | PHASE3 |
| NCT02140255 | RECRUITING | HIV Infection |
National Institute of Allergy and Infectious Diseases (NIAID) |
2015-01-23 | PHASE1; PHASE2 |
| NCT07601074 | RECRUITING | Human Papilloma Virus (HPV); High-risk Human Papillomavirus Infection |
Daré Bioscience, Inc. |
2026-07-17 | PHASE2 |
| NCT05334004 | RECRUITING | High-Grade Anal Intraepithelial Neoplasia |
University of Wisconsin, Madison |
2023-12-19 | PHASE1 |
| NCT05041907 | RECRUITING | COVID-19 |
University of Oxford |
2021-09-30 | PHASE2 |
| NCT05261139 | RECRUITING | COVID-19 |
Pfizer |
2022-03-07 | PHASE3 |
| NCT02735707 | RECRUITING | Community-acquired Pneumonia, Influenza, COVID-19 |
UMC Utrecht |
2016-04-11 | PHASE3 |
| NCT06792214 | RECRUITING | SARS CoV-2 Post-Acute Sequelae |
Mount Sinai Hospital, Canada |
2025-01-03 | PHASE4 |
| NCT05852873 | ACTIVE_NOT_RECRUITING | Post COVID-19 Condition, Unspecified; SARS-CoV2 Infection; COVID-19 |
Haukeland University Hospital |
2023-05-12 | PHASE3 |
| NCT04483960 | UNKNOWN | SARS-CoV-2 Infection (COVID-19) |
University of Melbourne |
2020-07-28 | PHASE3 |
| NCT06139796 | WITHDRAWN | HIV Infections |
PENTA Foundation |
2025-02-01 | PHASE1; PHASE2 |
| NCT05938140 | UNKNOWN | COVID-19; Renal Insufficiency, Chronic |
Chinese PLA General Hospital |
2023-06-22 | PHASE4 |
| NCT05386472 | TERMINATED | COVID-19 |
Pfizer |
2022-06-22 | PHASE1 |
| NCT04022967 | UNKNOWN | HIV-1-infection |
ANRS, Emerging Infectious Diseases |
2020-09-21 | PHASE3 |
| NCT06397144 | Not yet recruiting | Biological Availability|Healthy Participants |
Pfizer |
2025-02-14 | Phase 1 |
| NCT05925140 | UNKNOWN | COVID-19; Hospitalized COVID-19 Patients |
Lebanese University |
2020-03-28 | PHASE1 |
| NCT05823896 | COMPLETED | Post-COVID-19 Syndrome; Long COVID; Long Covid19; COVID-19; POTS - Postural Orthostatic Tachycardia Syndrome; Post COVID-19 Condition; Post-COVID Syndrome; Post COVID-19 Condition, Unspecified; Postinfectious Inflammation; Postinfectious Disorder |
Karolinska Institutet |
2023-05-01 | PHASE2 |
| NCT06139796 | Not yet recruiting | HIV Infections |
PENTA Foundation|AMS-PHPT Research Collaboration|Institut National de la Santé Et de la Recherche Médicale France|Centre Mère et Enfant de la Fondation Chantal Biya|Centre Hospitalier National d''Enfants Albert Royer|University of Zimbabwe Clinical Research Centre (UZCRC)|Baylor College of Medicine |
2024-06 | Phase 1|Phase 2 |
| NCT05953545 | WITHDRAWN | Chronic Hepatitis Delta |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2024-05-22 | PHASE2 |
| NCT05953545 | Not yet recruiting | Chronic Hepatitis Delta |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) |
2024-05-15 | Phase 2 |
| NCT06291831 | Active not recruiting | COVID-19 |
Pfizer |
2024-03-13 | -- |
| NCT05441215 | COMPLETED | Healthy Participants |
Pfizer |
2022-12-12 | PHASE1 |
| NCT05731804 | UNKNOWN | Renal Impairment; Hepatic Impairment |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
2023-03-01 | PHASE1 |
| NCT06085924 | Recruiting | COVID-19 |
Pfizer |
2023-11-14 | -- |
| NCT05321394 | COMPLETED | COVID-19 |
Azienda Ospedaliera Universitaria Integrata Verona |
2022-03-07 | PHASE3 |
| NCT06016556 | Completed | Covid-19 |
Pfizer |
2023-10-17 | -- |
| NCT05826249 | UNKNOWN | Elder |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
2023-04-07 | PHASE1 |
| NCT05545319 | WITHDRAWN | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2); Coronavirus Disease 2019 (COVID-19); Immunocompromised; Hospitalization; Child, Hospitalized |
Pfizer |
2022-12-13 | PHASE2 |
| NCT05898672 | COMPLETED | Pharmacokinetics; Healthy Volunteers |
Pfizer |
2023-06-09 | PHASE1 |
| NCT06087055 | COMPLETED | Healthy Participant |
Fujian Akeylink Biotechnology Co., Ltd. |
2023-05-12 | PHASE1 |
| NCT05656443 | COMPLETED | COVID-19 Pneumonia |
Fujian Akeylink Biotechnology Co., Ltd. |
2022-12-19 | PHASE2; PHASE3 |
| NCT05690646 | COMPLETED | Cardiac Surgery |
China National Center for Cardiovascular Diseases |
2023-01-28 | PHASE4 |
| NCT06205329 | COMPLETED | Healthy Participants |
Westlake Pharmaceuticals (Hangzhou) Co., Ltd. |
2022-10-03 | PHASE1 |
| NCT05506176 | COMPLETED | COVID-19 |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
2022-08-19 | PHASE2; PHASE3 |
| NCT05544786 | COMPLETED | Biological Availability |
Pfizer |
2022-09-28 | PHASE1 |
| NCT02437110 | COMPLETED | Amyotrophic Lateral Sclerosis |
National Institute of Neurological Disorders and Stroke (NINDS) |
2019-04-01 | PHASE1 |
| NCT05692570 | COMPLETED | Drug-drug Interaction |
Pyramid Biosciences |
2022-09-09 | PHASE1 |
| NCT03017872 | UNKNOWN | HIV Infections |
Kirby Institute |
2017-11-23 | PHASE4 |
| NCT05525910 | COMPLETED | Biological Availability; Healthy Participants |
Pfizer |
2022-08-31 | PHASE1 |
| NCT05373446 | UNKNOWN | COVID-19 |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
2022-05-20 | PHASE2 |
| NCT03719313 | COMPLETED | Hepatitis Delta Virus |
Eiger BioPharmaceuticals |
2018-12-01 | PHASE3 |
| NCT05339646 | UNKNOWN | Healthy Participants |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
2022-04-07 | PHASE1 |
| NCT05369676 | COMPLETED | COVID-19 Patients |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
2022-05-12 | PHASE1; PHASE2 |
| NCT05829551 | COMPLETED | COVID-19 (Coronavirus Disease 2019) |
Guangdong Raynovent Biotech Co., Ltd |
2022-05-20 | PHASE1 |
| NCT05011513 | TERMINATED | COVID-19 |
Pfizer |
2021-08-25 | PHASE2; PHASE3 |
| NCT04147208 | COMPLETED | Chronic HBV Infection |
Sunshine Lake Pharma Co., Ltd. |
2019-02-28 | PHASE2 |
| NCT05366192 | COMPLETED | Safety Issues |
RenJi Hospital |
2022-05-06 | PHASE4 |
| NCT05601167 | COMPLETED | COVID-19 |
Promomed, LLC |
2021-02-17 | PHASE3 |
| NCT05263921 | COMPLETED | Bioavailability |
Pfizer |
2022-03-10 | PHASE1 |
| NCT05263895 | COMPLETED | Bioavailability |
Pfizer |
2022-03-03 | PHASE1 |
| NCT05339334 | COMPLETED | Healthy Participants |
Pfizer |
2022-03-10 | PHASE1 |
| NCT05047601 | COMPLETED | COVID-19 |
Pfizer |
2021-09-09 | PHASE2; PHASE3 |
| NCT03602690 | UNKNOWN | HIV/AIDS |
ANRS, Emerging Infectious Diseases |
2018-10-04 | PHASE2 |
| NCT05011812 | COMPLETED | Covid19 |
Pardes Biosciences, Inc. |
2021-08-14 | PHASE1 |
| NCT04390152 | TERMINATED | Acute Respiratory Distress Syndrome |
BioXcellerator |
2020-01-13 | PHASE1; PHASE2 |
| NCT05032950 | COMPLETED | Healthy Participants |
Pfizer |
2021-09-17 | PHASE1 |
| NCT05005312 | COMPLETED | Hepatic Impairment |
Pfizer |
2021-08-31 | PHASE1 |
| NCT04499677 | COMPLETED | COVID-19 |
University College, London |
2020-09-24 | PHASE2 |
| NCT04466241 | COMPLETED | COVID-19; COVID-19 Drug Treatment; Severe Acute Respiratory Syndrome Coronavirus 2 |
ANRS, Emerging Infectious Diseases |
2020-11-27 | PHASE2; PHASE3 |
| NCT04455958 | WITHDRAWN | Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Symptomatic COVID-19 Infection Laboratory-Confirmed |
OHSU Knight Cancer Institute |
2021-05-01 | PHASE2 |
| NCT04630002 | COMPLETED | HIV Infections |
ViiV Healthcare |
2020-10-28 | PHASE1 |
| NCT04229290 | COMPLETED | HIV-1-infection |
University of Nairobi |
2020-02-12 | PHASE4 |
| NCT04380818 | UNKNOWN | Pneumonia, Viral |
Grupo de Investigación Clínica en Oncología Radioterapia |
2020-06-05 | |
| NCT04321174 | UNKNOWN | Coronavirus Infections; Post-exposure Prophylaxis |
Unity Health Toronto |
2020-04-17 | PHASE3 |
| NCT01281813 | COMPLETED | HIV-1 Infections |
Janssen Sciences Ireland UC |
2011-08-08 | PHASE3 |
| NCT04385719 | COMPLETED | Ebola; HIV/AIDS |
Makerere University |
2021-05-05 | PHASE2 |
| NCT04459702 | WITHDRAWN | COVID; COVID-19; Corona Virus Infection; Coronavirus Infection; Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere; Coronavirus-19; SARS-CoV 2; SARS Pneumonia |
ProgenaBiome |
2020-07 | PHASE2 |
| NCT02219490 | COMPLETED | Chronic Hepatitis C Virus (HCV) Infection Genotype 1 |
AbbVie |
2014-10-30 | PHASE3 |
| NCT04459286 | TERMINATED | Covid-19 |
Obafemi Awolowo University |
2020-10-09 | PHASE2 |
| NCT02555943 | COMPLETED | Chronic Hepatitis C Infection; HBV Coinfection; Hepatitis B Reactivation |
Humanity and Health Research Centre |
2015-02 | PHASE2; PHASE3 |
| NCT04208061 | COMPLETED | Healthy |
Janssen Research & Development, LLC |
2019-12-18 | PHASE1 |
| NCT02968641 | WITHDRAWN | Chronic Delta Hepatitis |
Eiger BioPharmaceuticals |
PHASE2 | |
| NCT04403100 | UNKNOWN | COVID-19; Coronavirus Infection; Virus Disease; Acute Respiratory Infection; SARS-CoV Infection |
Cardresearch |
2020-06-03 | PHASE3 |
| NCT04251871 | UNKNOWN | Pneumonia Caused by Human Coronavirus (Disorder) |
Beijing 302 Hospital |
2020-01-22 | |
| NCT03988452 | UNKNOWN | Human Immunodeficiency Virus |
Makerere University |
2019-07-30 | PHASE3 |
| NCT04295551 | UNKNOWN | COVID-19 |
Jiangxi Qingfeng Pharmaceutical Co. Ltd. |
2020-03-14 | |
| NCT04255017 | UNKNOWN | 2019-nCoV |
Tongji Hospital |
2020-02-01 | PHASE4 |
| NCT04261270 | UNKNOWN | 2019-nCoV Pneumonia |
Tongji Hospital |
2020-02-01 | PHASE3 |
| NCT02845843 | COMPLETED | Middle East Respiratory Syndrome Coronavirus (MERS-CoV) |
King Abdullah International Medical Research Center |
2016-07 | PHASE2; PHASE3 |
| NCT04307693 | TERMINATED | COVID-19 |
Asan Medical Center |
2020-03-11 | PHASE2 |
| NCT04343768 | COMPLETED | COVID-19 |
Shahid Beheshti University of Medical Sciences |
2020-04-09 | PHASE2 |
| NCT04350684 | UNKNOWN | COVID-19 |
Shahid Beheshti University of Medical Sciences |
2020-04-15 | PHASE4 |
| NCT04331470 | UNKNOWN | COVID-19 |
Fasa University of Medical Sciences |
2020-04-04 | PHASE2; PHASE3 |
| NCT04376814 | COMPLETED | COVID-19; Favipiravir; Kaletra; Hydroxychloroquine; Lopinavir/Ritonavir |
Baqiyatallah Medical Sciences University |
2020-03-29 | |
| NCT05084456 | WITHDRAWN | Solid Tumor, Adult; Impaired Liver Function |
Modra Pharmaceuticals |
2017-07 | PHASE1 |
| NCT02337322 | UNKNOWN | Acquired Immune Deficiency Syndrome Virus |
Juan A. Arnaiz |
2015-03-31 | PHASE4 |
| NCT03589027 | UNKNOWN | HIV-1-infection; Contraception |
Makerere University |
2018-08-07 | PHASE2 |
| NCT02150993 | COMPLETED | HIV-2 Infection |
ANRS, Emerging Infectious Diseases |
2016-01-26 | PHASE2; PHASE3 |
| NCT03549832 | COMPLETED | HCV Coinfection |
Assiut University |
2018-01-01 | |
| NCT01792570 | COMPLETED | Human Immunodeficiency Virus |
ASST Fatebenefratelli Sacco |
2014-09-30 | PHASE3 |
| NCT03362814 | COMPLETED | HCV |
Ascletis Pharmaceuticals Co., Ltd. |
2017-07-01 | PHASE2; PHASE3 |
| NCT03892161 | TERMINATED | HIV Infections |
University of Cape Town |
2018-04-12 | PHASE1 |
| NCT02652793 | COMPLETED | Human Immunodeficiency Virus |
Judit Pich |
2015-11 | |
| NCT02874066 | COMPLETED | Hepatitis Viruses |
National Taiwan University Hospital |
2017-03-13 | PHASE4 |
| NCT03485846 | COMPLETED | Chronic Hepatitis C Genotype 1b |
R-Pharm |
2017-11-27 | PHASE2 |
| NCT03499639 | COMPLETED | End-stage Renal Disease; HCV Coinfection |
Assiut University |
2018-05-01 | PHASE4 |
| NCT03662568 | COMPLETED | Chronic Hepatitis B |
Sunshine Lake Pharma Co., Ltd. |
2018-06-26 | PHASE1 |
| NCT02806362 | WITHDRAWN | Chronic Hepatitis C Virus |
AbbVie |
2016-09 | PHASE3 |
| NCT02194998 | TERMINATED | HIV Infections; Hepatitis C |
National Institute of Allergy and Infectious Diseases (NIAID) |
2015-09-16 | PHASE2 |
| NCT01125696 | COMPLETED | HIV; Hepatitis B |
Centers for Disease Control and Prevention |
2012-05 | PHASE2 |
| NCT02369965 | COMPLETED | HIV Infections; AIDS |
Frontier Biotechnologies Inc. |
2014-02-19 | PHASE3 |
| NCT02646111 | UNKNOWN | Hepatitis C |
Tel-Aviv Sourasky Medical Center |
2016-01 | PHASE3 |
| NCT03708861 | WITHDRAWN | HIV Infection |
University of Turin, Italy |
2016-01 | PHASE3 |
| NCT02473328 | COMPLETED | HIV-1 Infection |
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida |
2015-06 | PHASE2 |
| NCT01138605 | COMPLETED | HIV-1 Infections |
Janssen Sciences Ireland UC |
2010-10-13 | PHASE2 |
| NCT03234036 | COMPLETED | Infection, Human Immunodeficiency Virus; HIV Infections |
GlaxoSmithKline |
2017-08-02 | PHASE1 |
| NCT01923311 | TERMINATED | Acquired Immune Deficiency Syndrome (AIDS); HIV Infections |
Gilead Sciences |
2013-08-26 | PHASE2; PHASE3 |
| NCT02652624 | COMPLETED | HIV-1 Infection |
Gilead Sciences |
2016-02-19 | PHASE3 |
| NCT04378608 | COMPLETED | Hepatitis C Virus Infection |
Beni-Suef University |
2017-01-05 | PHASE1; PHASE2 |
| NCT02735863 | COMPLETED | HIV Infection |
Abivax S.A. |
2016-05 | PHASE2 |
| NCT02770508 | COMPLETED | HIV-1 Infection |
Fundación Huésped |
2015-11 | PHASE4 |
| NCT02470650 | WITHDRAWN | Patient Compliance; Antiretroviral Therapy Intolerance |
Juan A. Arnaiz |
2015-06 | PHASE4 |
| NCT02430194 | COMPLETED | Chronic Hepatitis D Infection |
Eiger BioPharmaceuticals |
2014-12 | PHASE2 |
| NCT02511431 | COMPLETED | Hepatitis D |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2015-07-29 | PHASE2 |
| NCT01601626 | TERMINATED | HIV Infection; Tuberculosis |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2013-07-13 | PHASE2 |
| NCT02503462 | TERMINATED | AIDS-related Dementia Complex |
University Hospital, Basel, Switzerland |
2015-07 | PHASE4 |
| NCT02207088 | COMPLETED | Chronic Hepatitis C; Hepatitis C Virus; Compensated Cirrhosis; Severe Renal Impairment; End-stage Renal Disease |
AbbVie |
2014-09-23 | PHASE3 |
| NCT02795754 | COMPLETED | Infection, Human Immunodeficiency Virus |
GlaxoSmithKline |
2016-03 | PHASE1 |
| NCT01869634 | COMPLETED | Human Immunodeficiency Virus Infection |
University of California, Davis |
2013-06 | PHASE4 |
| NCT01782495 | COMPLETED | Chronic Hepatitis C Infection |
AbbVie |
2013-02-25 | PHASE2 |
| NCT03020004 | COMPLETED | Chronic Hepatitis C |
Ascletis Pharmaceuticals Co., Ltd. |
2016-01 | PHASE2 |
| NCT02609659 | COMPLETED | Hepatitis C Virus (HCV) |
AbbVie |
2015-10-28 | PHASE3 |
| NCT02517515 | COMPLETED | Hepatitis C Virus (HCV) |
AbbVie |
2015-07 | PHASE3 |
| NCT01773070 | COMPLETED | Hepatitis C |
AbbVie (prior sponsor, Abbott) |
2013-06 | PHASE3 |
| NCT01061151 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2011-03-01 | PHASE3 |
| NCT02517528 | COMPLETED | Chronic Hepatitis C Virus (HCV) |
AbbVie |
2015-07-20 | PHASE3 |
| NCT02582632 | COMPLETED | Hepatitis C Infection; Hepatitis C Virus |
AbbVie |
2015-11-24 | PHASE3 |
| NCT03020134 | COMPLETED | Healthy |
Ascletis Pharmaceuticals Co., Ltd. |
2016-07-15 | PHASE1 |
| NCT00855335 | COMPLETED | HIV; HIV Infections; Pregnancy |
Janssen Scientific Affairs, LLC |
2009-04-09 | PHASE3 |
| NCT02265237 | COMPLETED | Hepatitis C Virus |
AbbVie |
2014-10-28 | PHASE3 |
| NCT01939197 | COMPLETED | Hepatitis C Virus Infection; Human Immunodeficiency Virus Infection; Chronic Hepatitis C; Compensated Cirrhosis and Non-cirrhotics |
AbbVie |
2013-08-30 | PHASE2; PHASE3 |
| NCT02198443 | COMPLETED | HIV |
Fundacion Clinic per a la Recerca Biomédica |
2015-06-06 | PHASE4 |
| NCT02442271 | COMPLETED | Chronic Hepatitis C Infection |
AbbVie |
2015-04-27 | PHASE3 |
| NCT02219672 | UNKNOWN | AIDS/HIV PROBLEM |
Peking Union Medical College |
2014-07 | PHASE3 |
| NCT01632891 | COMPLETED | HIV-1 Infection; Pf Subclinical Parasitemia |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2014-01-10 | PHASE1; PHASE2 |
| NCT02542852 | COMPLETED | HIV-1 Infection |
Castagna Antonella |
2015-09 | PHASE2 |
| NCT01599364 | COMPLETED | Human Immunodeficiency Virus |
Catholic University of the Sacred Heart |
2014-04 | PHASE4 |
| NCT02159599 | COMPLETED | HIV Infection |
Fundacion SEIMC-GESIDA |
2014-07 | PHASE4 |
| NCT02493855 | COMPLETED | Chronic Hepatitis C; Hepatitis C (HCV); Hepatitis C Genotype 1a |
AbbVie |
2015-06 | PHASE2 |
| NCT01231685 | COMPLETED | HIV; Hepatitis C; Liver Fibrosis |
McGill University Health Centre/Research Institute of the McGill University Health Centre |
2011-12 | PHASE2 |
| NCT01003990 | COMPLETED | HIV |
Bristol-Myers Squibb |
2002-10 | PHASE3 |
| NCT02565888 | COMPLETED | Hepatitis C; HIV |
Radboud University Medical Center |
2015-11 | PHASE1 |
| NCT02216422 | COMPLETED | Chronic Hepatitis C Virus (HCV) Infection |
AbbVie |
2014-09 | PHASE3 |
| NCT02399345 | COMPLETED | Chronic Hepatitis C Virus (HCV Infection Genotype 1) |
AbbVie |
2015-03 | PHASE3 |
| NCT01680536 | COMPLETED | HIV |
St Stephens Aids Trust |
2012-11 | PHASE4 |
| NCT03019991 | COMPLETED | Healthy |
Ascletis Pharmaceuticals Co., Ltd. |
2015-10 | PHASE1 |
| NCT01966822 | COMPLETED | HIV-1 Infection |
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia |
2014-01 | PHASE3 |
| NCT01910402 | COMPLETED | Infection, Human Immunodeficiency Virus; HIV Infections |
ViiV Healthcare |
2013-08-22 | PHASE3 |
| NCT02534870 | COMPLETED | Healthy Volunteer |
AbbVie |
2015-09 | PHASE1 |
| NCT01935830 | COMPLETED | Healthy Volunteers |
Washington University School of Medicine |
2013-08 | EARLY_PHASE1 |
| NCT02289495 | TERMINATED | Infection, Human Immunodeficiency Virus |
GlaxoSmithKline |
2014-11-18 | PHASE1 |
| NCT02219503 | COMPLETED | Chronic Hepatitis C Infection; Compensated Cirrhosis |
AbbVie |
2014-09 | PHASE3 |
| NCT01852604 | COMPLETED | Chronic Hepatitis C Virus |
Merck Sharp & Dohme LLC |
2013-03 | PHASE2 |
| NCT02023112 | COMPLETED | Hepatitis C Virus |
AbbVie |
2014-01 | PHASE3 |
| NCT02322957 | COMPLETED | Acute Herpes Zoster |
ContraVir Pharmaceuticals, Inc. |
2015-02 | PHASE1 |
| NCT00445146 | COMPLETED | HIV Infections |
Gilead Sciences |
2007-02 | PHASE2 |
| NCT01679964 | COMPLETED | HIV Infection; Adverse Drug Reaction; Quality of Life |
Lin, Hsi-Hsun, M.D. |
2012-07 | PHASE4 |
| NCT01749150 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2013-04 | PHASE2 |
| NCT01351740 | COMPLETED | HIV Infection |
University of British Columbia |
2011-07 | PHASE4 |
| NCT02023450 | UNKNOWN | Pulmonary Arterial Hypertension |
The Third Xiangya Hospital of Central South University |
2013-12 | EARLY_PHASE1 |
| NCT01146873 | COMPLETED | HIV/AIDS; HIV Infections |
Columbia University |
2010-07 | PHASE3 |
| NCT01825980 | COMPLETED | Hepatitis C |
Novartis Pharmaceuticals |
2013-03 | PHASE1; PHASE2 |
| NCT01803074 | COMPLETED | Infection, Human Immunodeficiency Virus; HIV Infections |
ViiV Healthcare |
2013-04-04 | PHASE2 |
| NCT02034838 | COMPLETED | HIV Infection |
Ottawa Hospital Research Institute |
2014-01 | PHASE1 |
| NCT01854697 | COMPLETED | Chronic Hepatitis C Infection |
AbbVie |
2013-03 | PHASE3 |
| NCT01691794 | COMPLETED | HIV, Pediatric |
Bristol-Myers Squibb |
2012-11-30 | PHASE4 |
| NCT02203461 | COMPLETED | Insulin Resistance |
Technical University of Munich |
2014-07 | PHASE1 |
| NCT01453933 | UNKNOWN | HIV Infection; Endothelial Dysfunction |
UMC Utrecht |
2012-01 | PHASE4 |
| NCT01335698 | COMPLETED | HIV |
Bristol-Myers Squibb |
2011-05-27 | PHASE3 |
| NCT01724086 | COMPLETED | Chronic Hepatitis C |
Janssen R&D Ireland |
2012-10 | PHASE2 |
| NCT01935674 | COMPLETED | HIV; Hypercholesterolaemia |
Juan A. Arnaiz |
2013-09 | PHASE4 |
| NCT01009437 | COMPLETED | Breast Cancer |
Masonic Cancer Center, University of Minnesota |
2010-05-26 | PHASE1 |
| NCT01258439 | COMPLETED | HIV; Cardiovascular Disease |
St Vincent's Hospital, Sydney |
2010-11 | PHASE4 |
| NCT02159352 | COMPLETED | Hepatitis C |
Bristol-Myers Squibb |
2014-06 | PHASE1 |
| NCT01448707 | COMPLETED | Human Immunodeficiency Virus (HIV) Infections; Acquired Immunodeficiency Syndrome (AIDS) Virus |
Janssen-Cilag International NV |
2012-03-15 | PHASE3 |
| NCT01533272 | COMPLETED | HIV Infection |
Hospital Clinic of Barcelona |
2012-02 | PHASE4 |
| NCT01685203 | COMPLETED | Hepatitis C, Chronic |
AbbVie (prior sponsor, Abbott) |
2012-08 | PHASE2 |
| NCT02063360 | COMPLETED | Infection, Human Immunodeficiency Virus |
ViiV Healthcare |
2014-02-01 | PHASE1 |
| NCT01423812 | COMPLETED | HIV |
Ruth M. Rothstein CORE Center |
2012-01 | PHASE4 |
| NCT01672983 | COMPLETED | Chronic Hepatitis C Infection |
AbbVie (prior sponsor, Abbott) |
2012-07 | PHASE2 |
| NCT01343225 | UNKNOWN | HIV |
East Carolina University |
2011-05 | PHASE4 |
| NCT01471821 | COMPLETED | HIV Infection |
Juan A. Arnaiz |
2011-10 | PHASE4 |
| NCT02064842 | COMPLETED | Healthy |
Janssen R&D Ireland |
2014-02 | PHASE1 |
| NCT01579019 | WITHDRAWN | Hepatitis C, Chronic |
Hoffmann-La Roche |
2012-07 | PHASE2 |
| NCT01458977 | COMPLETED | HIV; Dyslipidemia |
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia |
2012-01 | PHASE4 |
| NCT01671982 | COMPLETED | HIV |
Institut de Recherche pour le Developpement |
2012-08 | PHASE1 |
| NCT01704755 | COMPLETED | Chronic Hepatitis C Infection; Compensated Cirrhosis |
AbbVie (prior sponsor, Abbott) |
2012-10 | PHASE3 |
| NCT01759875 | COMPLETED | Healthy |
University of California, San Francisco |
2013-01 | PHASE1 |
| NCT01674725 | COMPLETED | Chronic Hepatitis C Infection |
AbbVie (prior sponsor, Abbott) |
2012-08 | PHASE3 |
| NCT01172535 | COMPLETED | HIV |
National Institute of Allergy and Infectious Diseases (NIAID) |
2010-11 | PHASE2; PHASE3 |
| NCT01185873 | COMPLETED | Healthy Volunteer |
Hoffmann-La Roche |
2011-02 | PHASE1 |
| NCT01475838 | COMPLETED | Acquired Immunodeficiency Syndrome; HIV Infections |
Gilead Sciences |
2011-11 | PHASE3 |
| NCT01715415 | COMPLETED | Chronic Hepatitis C Infection |
AbbVie (prior sponsor, Abbott) |
2012-11 | PHASE3 |
| NCT01716585 | COMPLETED | Chronic Hepatitis C Infection |
AbbVie (prior sponsor, Abbott) |
2012-11 | PHASE3 |
| NCT01483742 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2012-04 | PHASE2 |
| NCT01332227 | COMPLETED | HIV, Combination Therapy |
Bristol-Myers Squibb |
2011-10 | PHASE4 |
| NCT01516970 | COMPLETED | Human Immunodeficiency Virus (HIV) |
Janssen-Cilag G.m.b.H |
2011-11-25 | PHASE3 |
| NCT01565889 | COMPLETED | Hepatitis C; HIV |
Gilead Sciences |
2012-03 | PHASE1; PHASE2 |
| NCT01907724 | COMPLETED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2013-05 | PHASE1 |
| NCT00946595 | COMPLETED | HIV Infections |
French National Agency for Research on AIDS and Viral Hepatitis |
2009-11 | PHASE2; PHASE3 |
| NCT01274780 | COMPLETED | HIV-1 |
Juan A. Arnaiz |
2011-05 | PHASE4 |
| NCT01118871 | TERMINATED | HIV; HIV Infections |
Imperial College London |
2010-05 | PHASE4 |
| NCT01714154 | COMPLETED | Healthy Volunteer |
Hoffmann-La Roche |
2012-11 | PHASE1 |
| NCT01449929 | COMPLETED | Infection, Human Immunodeficiency Virus |
ViiV Healthcare |
2011-10-31 | PHASE3 |
| NCT01818856 | COMPLETED | Hepatitis C, Chronic; HIV Infection |
Hospitales Universitarios Virgen del Rocío |
2012-12 | PHASE1 |
| NCT00877591 | COMPLETED | Opioid Dependency; HIV Infections |
University of California, San Francisco |
2008-04 | PHASE1 |
| NCT01813552 | COMPLETED | Chronic Hepatitis C Infection |
Merck Sharp & Dohme LLC |
2013-02 | PHASE1 |
| NCT01464827 | COMPLETED | Chronic Hepatitis C; Hepatitis C (HCV); Hepatitis C Genotype 1 |
AbbVie (prior sponsor, Abbott) |
2011-10 | PHASE2 |
| NCT01384734 | COMPLETED | Infection, Human Immunodeficiency Virus |
ViiV Healthcare |
2011-07-26 | PHASE2 |
| NCT01583439 | TERMINATED | HIV Infections |
Harvard School of Public Health (HSPH) |
2012-09 | |
| NCT01656109 | COMPLETED | HIV |
The HIV Netherlands Australia Thailand Research Collaboration |
2011-07 | PHASE2 |
| NCT01620944 | TERMINATED | HIV |
Bristol-Myers Squibb |
2012-07-31 | PHASE3 |
| NCT00978068 | COMPLETED | Malaria; HIV Infections |
University of California, San Francisco |
2009-09 | PHASE3 |
| NCT01331850 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2011-05 | PHASE2 |
| NCT00540137 | COMPLETED | HIV Infections |
Imperial College London |
2007-07 | PHASE4 |
| NCT01105611 | UNKNOWN | HIV Infections; Hepatitis C |
St. James's Hospital, Ireland |
2010-08 | PHASE4 |
| NCT01220947 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2010-11 | PHASE2 |
| NCT01189695 | COMPLETED | HIV; AIDS; Lopinavir; Treatment Failure |
Bamrasnaradura Infectious Diseases Institute |
2010-12 | PHASE4 |
| NCT01654211 | COMPLETED | Healthy Volunteer |
Hoffmann-La Roche |
2012-07 | PHASE1 |
| NCT01099579 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
2010-10-13 | PHASE3 |
| NCT01278134 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2011-02 | PHASE2 |
| NCT01199939 | COMPLETED | Human Immunodeficiency Virus (HIV) |
Tibotec, Inc |
2010-05 | PHASE2 |
| NCT00994344 | COMPLETED | HIV Infections |
Germans Trias i Pujol Hospital |
2009-10 | PHASE4 |
| NCT01660477 | COMPLETED | Pharmacokinetics of Isavuconazole; Pharmacokinetics of Lopinavir/Ritonavir; Healthy Volunteers |
Astellas Pharma Global Development, Inc. |
2012-06 | PHASE1 |
| NCT01513122 | COMPLETED | HIV |
Kirby Institute |
2010-02 | PHASE4 |
| NCT00102960 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2005-07 | PHASE3 |
| NCT00608569 | COMPLETED | HIV Infections |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2009-03 | |
| NCT00605098 | COMPLETED | HIV Infections; Pregnancy |
Oswaldo Cruz Foundation |
2008-02 | PHASE4 |
| NCT00865007 | COMPLETED | HIV Infection; Lipodystrophy; HIV Infections |
Fundacion SEIMC-GESIDA |
2008-12 | PHASE4 |
| NCT01102972 | COMPLETED | Infection, Human Immunodeficiency Virus |
ViiV Healthcare |
2010-04 | PHASE4 |
| NCT01602822 | TERMINATED | HIV |
Kenneth H. Mayer, MD |
2012-02 | PHASE4 |
| NCT01237444 | COMPLETED | HIV Infection |
Pedro Cahn |
2010-12 | PHASE3 |
| NCT01475227 | COMPLETED | HIV Infection |
St Stephens Aids Trust |
2011-12 | PHASE4 |
| NCT01294761 | COMPLETED | HIV Infections |
National Center for Global Health and Medicine, Japan |
2011-02 | |
| NCT01348763 | COMPLETED | HIV |
Imperial College London |
2011-10 | PHASE1 |
| NCT01514968 | COMPLETED | Healthy Volunteer |
Hoffmann-La Roche |
2011-12 | PHASE1 |
| NCT01166477 | COMPLETED | HIV Infection |
Sociedad Andaluza de Enfermedades Infecciosas |
2010-01 | PHASE4 |
| NCT00802334 | COMPLETED | HIV |
The HIV Netherlands Australia Thailand Research Collaboration |
2008-01 | PHASE2 |
| NCT01194856 | TERMINATED | HIV Infection; Mitochondrial Dysfunction |
The Cleveland Clinic |
2010-10 | PHASE4 |
| NCT01458054 | COMPLETED | Hepatitis C |
GlaxoSmithKline |
2011-09-27 | PHASE1 |
| NCT01398293 | COMPLETED | Healthy Volunteer |
Hoffmann-La Roche |
2011-08 | PHASE1 |
| NCT01108510 | COMPLETED | HIV; HIV Infections |
Gilead Sciences |
2010-04 | PHASE3 |
| NCT01088516 | COMPLETED | HIV |
University of Zambia |
2008-12 | PHASE4 |
| NCT01772940 | COMPLETED | HIV-1 Infection |
Centre Hospitalier Universitaire Saint Pierre |
2008-12 | PHASE4 |
| NCT00234091 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-04 | PHASE3 |
| NCT01392755 | COMPLETED | Healthy Volunteer |
Hoffmann-La Roche |
2011-07 | PHASE1 |
| NCT01106586 | COMPLETED | HIV; HIV Infections |
Gilead Sciences |
2010-04 | PHASE3 |
| NCT01418274 | COMPLETED | Healthy Volunteer |
Hoffmann-La Roche |
2011-08 | PHASE1 |
| NCT01389544 | COMPLETED | Healthy Volunteer |
Hoffmann-La Roche |
2011-06 | PHASE1 |
| NCT00849160 | COMPLETED | HIV-1 Infection; HIV Infections |
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida |
2009-05 | PHASE3 |
| NCT01422369 | COMPLETED | Healthy |
Kowa Research Institute, Inc. |
2011-04 | PHASE4 |
| NCT01074008 | COMPLETED | Hepatitis C; HCV; Chronic Hepatitis C Infection; Hepatitis C Genotype 1 |
AbbVie (prior sponsor, Abbott) |
2010-03 | PHASE2 |
| NCT01231451 | WITHDRAWN | HIV Infection |
St Stephens Aids Trust |
2010-12 | PHASE1 |
| NCT01165645 | WITHDRAWN | Hodgkin Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage IV Adult Hodgkin Lymphoma |
Mayo Clinic |
2010-11 | |
| NCT00089583 | COMPLETED | Infection, Human Immunodeficiency Virus I |
ViiV Healthcare |
2004-07 | PHASE2 |
| NCT00335322 | COMPLETED | Human Immunodeficiency Virus (HIV) |
Kirby Institute |
2007-02 | PHASE4 |
| NCT00724711 | COMPLETED | HIV Infection |
Gilead Sciences |
2008-07 | PHASE4 |
| NCT01227590 | COMPLETED | Drug Interactions; Human Immunodeficiency Virus |
University of California, San Francisco |
2010-02 | PHASE1 |
| NCT00708162 | COMPLETED | HIV Infection |
Gilead Sciences |
2008-07 | PHASE3 |
| NCT00307151 | COMPLETED | HIV Infections |
International Maternal Pediatric Adolescent AIDS Clinical Trials Group |
2005-12 | PHASE2 |
| NCT00869960 | COMPLETED | Healthy |
University of Alabama at Birmingham |
2009-03 | PHASE4 |
| NCT01057433 | COMPLETED | Healthy Volunteers |
Kowa Research Institute, Inc. |
2010-01 | PHASE4 |
| NCT00775606 | TERMINATED | Acquired Immune Deficiency Syndrome |
Rush University Medical Center |
2008-10 | PHASE4 |
| NCT01010399 | COMPLETED | Hypertriglyceridemia; HIV Infection |
Felizarta, Franco, M.D. |
2009-09 | PHASE4 |
| NCT00266058 | COMPLETED | HIV Infections; Malaria |
University of California, San Francisco |
2005-12 | PHASE1 |
| NCT01209065 | COMPLETED | Infections, Human Immunodeficiency Virus and Herpesviridae |
ViiV Healthcare |
2010-09 | PHASE1 |
| NCT01140412 | TERMINATED | Healthy |
ViiV Healthcare |
2010-07 | PHASE1 |
| NCT00640887 | COMPLETED | HIV Infections; Tuberculosis |
French National Agency for Research on AIDS and Viral Hepatitis |
2009-02 | PHASE2 |
| NCT00296504 | COMPLETED | Infection, Human Immunodeficiency Virus |
ViiV Healthcare |
2001-11 | PHASE3 |
| NCT01156389 | COMPLETED | Malaria |
Medicines for Malaria Venture |
2010-07 | PHASE1 |
| NCT00919854 | COMPLETED | Human Immunodeficiency Virus 1 |
Tibotec Pharmaceuticals, Ireland |
2009-09 | PHASE2 |
| NCT01164488 | COMPLETED | Healthy Volunteer |
Hoffmann-La Roche |
2010-07 | PHASE1 |
| NCT00827112 | COMPLETED | Human Immunodeficiency Virus-1 |
ViiV Healthcare |
2009-03 | PHASE2 |
| NCT00437684 | UNKNOWN | HIV Infections; Hepatitis C |
IRCCS San Raffaele |
2007-02 | PHASE3 |
| NCT00437476 | UNKNOWN | HIV Infections; Hepatitis C |
IRCCS San Raffaele |
2007-02 | PHASE3 |
| NCT00765154 | TERMINATED | HIV |
St Stephens Aids Trust |
2008-10 | PHASE4 |
| NCT00440947 | COMPLETED | Infection, Human Immunodeficiency Virus I; HIV Infection |
ViiV Healthcare |
2007-03 | PHASE3 |
| NCT01009814 | COMPLETED | HIV Infections |
ViiV Healthcare |
2009-11-23 | PHASE2 |
| NCT00076999 | COMPLETED | HIV Infections |
Boehringer Ingelheim |
2003-11 | PHASE1 |
| NCT01073761 | COMPLETED | HIV; HIV Infections |
St Stephens Aids Trust |
2010-04 | PHASE1 |
| NCT00421551 | COMPLETED | HIV Infections |
French National Agency for Research on AIDS and Viral Hepatitis |
2007-03 | PHASE3 |
| NCT00885482 | COMPLETED | HIV Infections |
Catholic University of the Sacred Heart |
2009-05 | PHASE4 |
| NCT01091649 | COMPLETED | Healthy |
Abbott |
2010-02 | PHASE1 |
| NCT01046890 | COMPLETED | HIV Infections |
Germans Trias i Pujol Hospital |
2010-01 | PHASE4 |
| NCT00100646 | COMPLETED | HIV Infections |
The Wistar Institute |
2007-03 | |
| NCT00623597 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
2008-06 | PHASE2 |
| NCT00552240 | COMPLETED | HIV Infections |
Boehringer Ingelheim |
2007-09 | PHASE4 |
| NCT00632970 | TERMINATED | HIV Infections |
George Washington University |
2008-02 | PHASE4 |
| NCT00543101 | COMPLETED | HIV Infections |
Community Research Initiative of New England |
2007-10 | PHASE4 |
| NCT00768989 | TERMINATED | HIV |
Bristol-Myers Squibb |
2008-11 | PHASE2 |
| NCT01445223 | COMPLETED | HIV |
Göteborg University |
2004-04 | PHASE4 |
| NCT00892437 | COMPLETED | HIV-1 Infection |
Gilead Sciences |
2009-05 | PHASE2 |
| NCT00159224 | COMPLETED | HIV Infections |
Fundación Huésped |
2005-04 | PHASE4 |
| NCT01049685 | UNKNOWN | HIV Infections |
UPECLIN HC FM Botucatu Unesp |
2006-08 | PHASE4 |
| NCT00307502 | COMPLETED | HIV Infections |
Germans Trias i Pujol Hospital |
2005-01 | PHASE1 |
| NCT00118898 | COMPLETED | HIV Infections |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2005-09 | PHASE3 |
| NCT00711009 | COMPLETED | Human Immunodeficiency Virus Infection |
Abbott |
2008-07 | PHASE3 |
| NCT00630734 | COMPLETED | HIV Infections; Hyperlipidemia |
University of Colorado, Denver |
2008-02 | PHASE4 |
| NCT00772902 | COMPLETED | HIV-1 |
Gilead Sciences |
2008-10 | PHASE4 |
| NCT00885664 | COMPLETED | HIV Infections |
University of Cincinnati |
2005-10 | PHASE4 |
| NCT00838162 | COMPLETED | Human Immunodeficiency Virus Type 1 |
Tibotec Pharmaceuticals, Ireland |
2009-06 | PHASE2 |
| NCT00385645 | COMPLETED | HIV Infections |
Hospital Clinic of Barcelona |
2006-05 | PHASE4 |
| NCT00524368 | COMPLETED | Human Immunodeficiency Virus - Type 1 |
Tibotec Pharmaceuticals, Ireland |
2007-10 | PHASE3 |
| NCT00850044 | COMPLETED | HCV Infection |
AbbVie |
2009-02 | PHASE1 |
| NCT00909311 | COMPLETED | HCV Infection |
Abbott |
2009-05 | PHASE1 |
| NCT00817765 | COMPLETED | HIV Infection; Fungal Infection |
Radboud University Medical Center |
2009-01 | PHASE1 |
| NCT00611039 | COMPLETED | HIV Infections |
Germans Trias i Pujol Hospital |
2008-02 | PHASE4 |
| NCT00797745 | COMPLETED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2008-11 | PHASE2 |
| NCT00883935 | COMPLETED | Healthy Volunteer |
GlaxoSmithKline |
2009-04 | PHASE1 |
| NCT00867152 | COMPLETED | Healthy Volunteer |
ViiV Healthcare |
2009-04 | PHASE1 |
| NCT00810108 | COMPLETED | HIV/AIDS Treatment; HIV Infections |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
2006-06 | PHASE4 |
| NCT00260078 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-02 | PHASE1; PHASE2 |
| NCT00833378 | COMPLETED | Hepatitis C |
GlaxoSmithKline |
2009-01-19 | PHASE1 |
| NCT00270296 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-06 | PHASE2 |
| NCT00458302 | COMPLETED | HIV Infections; AIDS Virus; Human Immunodeficiency Virus; Acquired Immunodeficiency Syndrome Virus |
Janssen-Cilag International NV |
2007-06 | PHASE3 |
| NCT00438152 | COMPLETED | HIV Infections |
Royal Free Hampstead NHS Trust |
2006-09 | PHASE4 |
| NCT00887120 | COMPLETED | HIV Infections |
The HIV Netherlands Australia Thailand Research Collaboration |
2007-04 | PHASE2 |
| NCT00255840 | COMPLETED | HIV Infections |
CIPRA SA |
2006-07 | |
| NCT00326716 | COMPLETED | HIV Infection |
Bristol-Myers Squibb |
2006-06 | PHASE1 |
| NCT00966160 | COMPLETED | Acquired Immunodeficiency Syndrome; HIV Infections |
University of Cologne |
1999-01 | PHASE3 |
| NCT00744887 | COMPLETED | HIV; AIDS |
Tibotec Pharmaceuticals, Ireland |
2008-08 | PHASE1 |
| NCT00413153 | COMPLETED | HIV Infections |
Massachusetts General Hospital |
2006-05 | |
| NCT00661349 | TERMINATED | HIV Infections |
Germans Trias i Pujol Hospital |
2008-02 | PHASE4 |
| NCT00767117 | COMPLETED | HIV |
Tibotec Pharmaceuticals, Ireland |
2008-09 | PHASE1 |
| NCT00774735 | COMPLETED | Healthy Subjects; Infection, Human Immunodeficiency Virus |
GlaxoSmithKline |
2008-10 | PHASE1 |
| NCT00764465 | COMPLETED | Healthy |
Garden State Infectious Disease Associates, PA |
2008-10 | PHASE2 |
| NCT00528060 | COMPLETED | HIV Infections |
French National Agency for Research on AIDS and Viral Hepatitis |
2008-01 | PHASE2 |
| NCT00717067 | COMPLETED | Human Immunodeficiency Virus (HIV) Infection |
ViiV Healthcare |
2008-07 | PHASE4 |
| NCT00770042 | COMPLETED | Erectile Dysfunction |
VIVUS LLC |
2008-10 | PHASE1 |
| NCT02259855 | COMPLETED | Hepatic Insufficiency |
Boehringer Ingelheim |
2006-01-01 | PHASE1 |
| NCT00440271 | TERMINATED | HIV Infections |
Boehringer Ingelheim |
2007-02 | PHASE3 |
| NCT00775125 | COMPLETED | Hepatitis C; Telaprevir; HIV |
Tibotec BVBA |
2008-06 | PHASE1 |
| NCT00109590 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-06 | PHASE2 |
| NCT00144170 | COMPLETED | HIV Infections |
Boehringer Ingelheim |
2003-02 | PHASE3 |
| NCT00447902 | TERMINATED | HIV Infections |
Boehringer Ingelheim |
2007-03 | PHASE3 |
| NCT00517192 | TERMINATED | HIV Infections |
Boehringer Ingelheim |
2007-09 | PHASE3 |
| NCT00571961 | COMPLETED | HIV Infections |
Yale University |
2007-01 | |
| NCT00531999 | COMPLETED | HIV Infections |
St Stephens Aids Trust |
2007-10 | PHASE1 |
| NCT01081158 | COMPLETED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2007-07 | PHASE1 |
| NCT00646776 | COMPLETED | Antivirals/HIV |
Bristol-Myers Squibb |
2008-04 | PHASE1 |
| NCT00450580 | COMPLETED | Infection, Human Immunodeficiency Virus I; HIV-1 Infection |
ViiV Healthcare |
2007-03 | PHASE3 |
| NCT00474201 | COMPLETED | Healthy Volunteers |
National Institutes of Health Clinical Center (CC) |
2007-05 | |
| NCT02251795 | COMPLETED | Healthy |
Boehringer Ingelheim |
2007-08 | PHASE1 |
| NCT02183441 | COMPLETED | Healthy |
Boehringer Ingelheim |
2008-04 | PHASE1 |
| NCT02244190 | COMPLETED | Healthy |
Boehringer Ingelheim |
2008-04 | PHASE1 |
| NCT00337467 | COMPLETED | Human Immunodeficiency Virus (HIV) Infections |
Bristol-Myers Squibb |
2006-06 | PHASE3 |
| NCT00146328 | COMPLETED | HIV Infections |
Boehringer Ingelheim |
2001-04 | PHASE2; PHASE3 |
| NCT00379405 | COMPLETED | HIV Infections |
Germans Trias i Pujol Hospital |
2006-06 | PHASE4 |
| NCT00534352 | COMPLETED | HIV-1 Infection |
Tibotec, Inc |
2008-01 | PHASE2 |
| NCT00622206 | COMPLETED | HIV Infections |
The HIV Netherlands Australia Thailand Research Collaboration |
2008-01 | PHASE1; PHASE2 |
| NCT00460382 | COMPLETED | HIV Infections |
French National Agency for Research on AIDS and Viral Hepatitis |
2007-05 | PHASE2 |
| NCT00355719 | COMPLETED | HIV Infections |
Germans Trias i Pujol Hospital |
2007-01 | PHASE4 |
| NCT00143689 | COMPLETED | HIV; Mitochondrial Toxicity |
University of British Columbia |
2002-04 | PHASE4 |
| NCT00084149 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2004-02 | PHASE2 |
| NCT01891851 | COMPLETED | Healthy |
Tibotec Pharmaceuticals, Ireland |
2007-10 | PHASE1 |
| NCT00140751 | COMPLETED | HIV Infections |
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba |
2005-10 | PHASE3 |
| NCT00234975 | COMPLETED | HIV Infection |
AbbVie (prior sponsor, Abbott) |
2002-10 | PHASE4 |
| NCT00145561 | COMPLETED | HIV Infections |
Radboud University Medical Center |
2005-08 | PHASE1; PHASE2 |
| NCT00051831 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2003-10 | |
| NCT00335270 | COMPLETED | HIV |
Duke University |
2006-03 | PHASE4 |
| NCT00420355 | TERMINATED | HIV Infection |
University of Oklahoma |
2007-04 | PHASE4 |
| NCT02229760 | TERMINATED | HIV Infections |
Boehringer Ingelheim |
2006-08 | PHASE1; PHASE2 |
| NCT00105079 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
2005-04 | PHASE3 |
| NCT00135356 | COMPLETED | HIV-Associated Lipodystrophy Syndrome |
Bristol-Myers Squibb |
2005-07 | PHASE4 |
| NCT02226978 | COMPLETED | Healthy |
Boehringer Ingelheim |
2007-02 | PHASE1 |
| NCT00160329 | COMPLETED | Hyperlipidemia; HIV Infections |
Stanford University |
2004-01 | PHASE3 |
| NCT00312754 | TERMINATED | HIV Infections |
Bristol-Myers Squibb |
2005-06 | PHASE4 |
| NCT00477126 | COMPLETED | Healthy |
The HIV Netherlands Australia Thailand Research Collaboration |
2007-01 | PHASE1 |
| NCT00234923 | COMPLETED | HIV Infection |
Abbott |
2003-08 | PHASE3 |
| NCT00148759 | COMPLETED | HIV Infections |
Emory University |
2005-06 | PHASE4 |
| NCT02253940 | COMPLETED | Healthy |
Boehringer Ingelheim |
2006-10 | PHASE1 |
| NCT00393328 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
2006-11 | PHASE1 |
| NCT00648999 | COMPLETED | Human Immunodeficiency Virus |
AbbVie (prior sponsor, Abbott) |
2003-11 | PHASE4 |
| NCT00144105 | TERMINATED | HIV Infections |
Boehringer Ingelheim |
2004-02 | PHASE2 |
| NCT00362726 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
2006-09 | PHASE1 |
| NCT00720590 | COMPLETED | Endothelial Dysfunction |
Indiana University |
2003-11 | |
| NCT00357188 | COMPLETED | HIV Infections; Protease Inhibitor |
Bristol-Myers Squibb |
2006-07 | PHASE1 |
| NCT00352066 | COMPLETED | HIV Infection |
Avexa |
2006-07 | PHASE1 |
| NCT00162149 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
2005-10 | PHASE1 |
| NCT02243553 | COMPLETED | Healthy |
Boehringer Ingelheim |
2006-01 | PHASE1 |
| NCT00365339 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
2006-04 | PHASE1 |
| NCT00120393 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
2004-01 | PHASE3 |
| NCT00144287 | COMPLETED | HIV Infections |
Boehringer Ingelheim |
2004-05 | PHASE3 |
| NCT02253862 | COMPLETED | Healthy |
Boehringer Ingelheim |
2005-12 | PHASE1 |
| NCT02248883 | COMPLETED | Healthy |
Boehringer Ingelheim |
2005-12 | PHASE1 |
| NCT00135395 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
2004-05 | PHASE3 |
| NCT02253875 | COMPLETED | Healthy |
Boehringer Ingelheim |
2005-11 | PHASE1 |
| NCT00197197 | TERMINATED | HIV Infection |
GlaxoSmithKline |
2005-07 | PHASE3 |
| NCT02259868 | COMPLETED | Healthy |
Boehringer Ingelheim |
2005-06 | PHASE1 |
| NCT02256826 | COMPLETED | Healthy |
Boehringer Ingelheim |
2005-04 | PHASE1 |
| NCT02257021 | COMPLETED | Healthy |
Boehringer Ingelheim |
2005-02 | PHASE1 |
| NCT00004578 | COMPLETED | HIV Infections |
Abbott |
1997-11 | PHASE1; PHASE2 |
| NCT00014937 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT02253914 | COMPLETED | Healthy |
Boehringer Ingelheim |
2004-02 | PHASE1 |
| NCT02253953 | COMPLETED | Healthy |
Boehringer Ingelheim |
2002-11 | PHASE1 |
| NCT02251171 | COMPLETED | Healthy |
Boehringer Ingelheim |
2003-08 | PHASE1 |
| NCT00028301 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
2001-02 | PHASE3 |
| NCT02195466 | COMPLETED | Healthy |
Boehringer Ingelheim |
2003-06 | PHASE1 |
| NCT00046033 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT02245438 | TERMINATED | Healthy |
Boehringer Ingelheim |
2002-05 | PHASE1 |
| NCT02251873 | COMPLETED | Healthy |
Boehringer Ingelheim |
2001-09 | PHASE1 |
| NCT02239835 | TERMINATED | HIV Infections |
Boehringer Ingelheim |
1999-12 | PHASE2 |
| NCT02238314 | COMPLETED | HIV Infections |
Boehringer Ingelheim |
1999-01 | PHASE2 |
| NCT02251132 | COMPLETED | Healthy |
Boehringer Ingelheim |
2000-10 | PHASE1 |
| NCT02249130 | COMPLETED | HIV Infections |
Boehringer Ingelheim |
1999-03 | PHASE2 |
| NCT00116636 | COMPLETED | HIV Infections |
Therapeutic Concepts |
2005-06 | PHASE2 |
| NCT00002451 | UNKNOWN | HIV Infections |
Merck Sharp & Dohme LLC |
PHASE2 | |
| NCT00025727 | UNKNOWN | HIV Infections |
GlaxoSmithKline |
2001-05 | PHASE3 |
| NCT00063804 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00044837 | TERMINATED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00006339 | WITHDRAWN | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00102986 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2005-10 | |
| NCT00001688 | COMPLETED | HIV Infection |
National Cancer Institute (NCI) |
1998-01 | PHASE2 |
| NCT00122577 | TERMINATED | HIV Infections |
French National Agency for Research on AIDS and Viral Hepatitis |
2002-03 | PHASE2 |
| NCT01323257 | COMPLETED | Hepatitis C Virus |
Tibotec Pharmaceuticals, Ireland |
2011-03 | PHASE1 |
| NCT00005118 | UNKNOWN | HIV Infections |
Merck Sharp & Dohme LLC |
PHASE2 | |
| NCT00148785 | COMPLETED | HIV Infections |
Emory University |
2005-07 | PHASE4 |
| NCT00028366 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00002378 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
PHASE3 | |
| NCT00012519 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1; PHASE2 | |
| NCT00084058 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1; PHASE2 | |
| NCT00017992 | UNKNOWN | HIV Infections |
Triangle Pharmaceuticals |
PHASE2 | |
| NCT00002178 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
PHASE3 | |
| NCT00006578 | WITHDRAWN | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00038519 | COMPLETED | HIV Infections |
Abbott |
2001-04 | PHASE2; PHASE3 |
| NCT00002241 | UNKNOWN | HIV Infections |
Merck Sharp & Dohme LLC |
PHASE2 | |
| NCT00481182 | COMPLETED | Healthy Subjects |
GlaxoSmithKline |
2005-02 | PHASE1 |
| NCT00000924 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00004582 | COMPLETED | HIV Infections |
ViRx |
PHASE2 | |
| NCT00038636 | COMPLETED | HIV Infections |
Abbott |
2000-09 | PHASE3 |
| NCT00002201 | COMPLETED | HIV Infections |
Abbott |
||
| NCT00039975 | COMPLETED | HIV Infections; Cardiovascular Diseases; Hypertension |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00036452 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000822 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000919 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00006144 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2000-10 | PHASE2 |
| NCT00085943 | COMPLETED | HIV Infection; Infection, Human Immunodeficiency Virus |
GlaxoSmithKline |
2004-05 | PHASE3 |
| NCT00000952 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002447 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
1999-10 | PHASE3 |
| NCT00023218 | WITHDRAWN | HIV Infections; Hepatitis C |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00002448 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
1999-10 | PHASE3 |
| NCT00121017 | WITHDRAWN | HIV Infection; Hepatitis C |
Abbott |
PHASE2 | |
| NCT00001108 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00001091 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002361 | COMPLETED | HIV Infections |
Merck Sharp & Dohme LLC |
PHASE2 | |
| NCT01368783 | UNKNOWN | Atazanavir |
Asan Medical Center |
2011-06 | PHASE1 |
| NCT00000940 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
1999-05 | PHASE2 |
| NCT00000891 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000920 | COMPLETED | HIV Infections; Pregnancy |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00076414 | COMPLETED | Healthy |
National Institutes of Health Clinical Center (CC) |
2004-01 | PHASE1 |
| NCT00001087 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00001083 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00004583 | COMPLETED | HIV Infections |
Abbott |
1999-03 | PHASE3 |
| NCT00001766 | COMPLETED | HIV Infection |
National Institute of Allergy and Infectious Diseases (NIAID) |
1998-08 | PHASE1 |
| NCT00038532 | COMPLETED | HIV Infections |
Abbott |
2001-04 | PHASE2 |
| NCT00075907 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2004-07 | PHASE3 |
| NCT00114933 | COMPLETED | HIV Infection |
Arribas, Jose R., M.D. |
2005-01 | PHASE4 |
| NCT00000941 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002223 | COMPLETED | HIV Infections |
Abbott |
||
| NCT00028314 | COMPLETED | HIV Infections; Lipodystrophy; Wasting Disease |
National Institute of Allergy and Infectious Diseases (NIAID) |
2002-03 | |
| NCT00000906 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00080522 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2005-02 | |
| NCT00002374 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
PHASE3 | |
| NCT00162643 | UNKNOWN | Acquired Immunodeficiency Syndrome |
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
2004-12 | PHASE4 |
(data from https://clinicaltrials.gov, updated on 2026-06-10)
Check the
Ritonavir
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
Note: Technical data last updated: Sep 1, 2026.